FindTrial
Sign In

Clinical study of molecular pathological characteristics of radioiodine refractory differentiated thyroid carcinoma in guiding its accurate diagnosis and treatment

Clinical study of molecular pathological characteristics of radioiodine refractory differentiated thyroid carcinoma in guiding its accurate diagnosis and treatment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050685
Enrollment
Unknown
Registered
2021-09-02
Start date
2021-09-30
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radioiodine refractory differentiated thyroid carcinoma

Interventions

Case series:None

Sponsors

Tenth People's Hospital of Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. DTC patients who meet the above diagnostic criteria; 2. Ability to obtain tumor tissue by needle biopsy; 3. Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those with bleeding tendency or significantly prolonged coagulation time; 2. Patients with lung metastases who have uncontrollable cough or do not cooperate, and have bullous emphysema at the site where the puncture needle passes; 3. Severe pulmonary hypertension; 4. Cardiopulmonary function is poor.

Design outcomes

Primary

MeasureTime frame
gene mutation;—

Countries

China

Contacts

Public ContactMa Chao

Tenth People's Hospital of Tongji University

ponymachao@163.com+86 18721288964

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026